हिंदी में पढ़ें

Dr Reddy's Laboratories

Dr Reddy's Laboratories Q1 net profit soars 45% to Rs 663 crore

Dr Reddy's Laboratories Q1 net profit soars 45% to Rs 663 crore

Mon, Jul 29, 2019

Pharma major Dr Reddy's Laboratories (DRL) on Monday reported a handsome 45.31 per cent growth in net profit for the first quarter ended June.

Dr Reddys to spend upto $300 million on R&D in FY 20

Dr Reddys to spend upto $300 million on R&D in FY 20

Mon, May 20, 2019

The R&D spend for the quarter (January-March FY 19) is Rs 366 crore, that is USD 53 million and EBIT 9.19 per cent of the sales for the quarter, said Saumen Chakraborty, President, CFO and global head (HR) of Dr Reddy.

Dr Reddy's, KKR appoint ex Axis Bank chief Shikha Sharma as independent director

Dr Reddy's, KKR appoint ex Axis Bank chief Shikha Sharma as independent director

Fri, Feb 01, 2019

Sharma will advising them on areas for business growth, value-creation opportunities and strategic mergers and acquisitions, an official statement said.

TRENDING NOW

Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018

Pharma sector outlook 2019 in India: Expect big recovery in New Year; IPCA, Divis Lab champions of 2018

Mon, Dec 31, 2018

The sector has been volatile throughout the year due to constant news flow in the markets. Some giants of the sector witnessed objections over their manufacturing plants and medicine pricing in the U.S. markets.

Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%

Big blow to Dr Reddy's over opioid addiction treatment block in US; share price tanks a whopping 11%

Mon, Jul 16, 2018

Analysts at Jefferies believe injunction is a negative surprise for Dr Reddy’s and risks for FY20-22 EPS estimates have increased after the ruling. retain “underperform”, cuts TP to 1,850 rupees from 1,910 rupees

FAST MONEY: Phoenix Mills, Biocon among 20 intraday money-making ideas

FAST MONEY: Phoenix Mills, Biocon among 20 intraday money-making ideas

Mon, Jun 25, 2018

S&P500 mini futures fell as much as 0.5 per cent in early trade while MSCI's broadest index of Asia-Pacific shares outside Japan fell 0.2 per cent. Japan's Nikkeilost 0.4 percent.

Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions

Dr Reddy's last day on Sensex; stock rallies 20% in 8 sessions

Fri, Jun 15, 2018

Dr Reddy's share price gained as much as 20 per cent in the last 8 sessions, thanks to a renewed optimism on the sector. Nifty Pharma index itself gained 14 per cent during the same period. In Friday's trade, Nifty Pharma was the top sectoral gainer, led by gains in Dr Reddy's.

Sensex, Nifty reverse gains; Rupee at 10-week low as US Fed signals rate hike

Sensex, Nifty reverse gains; Rupee at 10-week low as US Fed signals rate hike

Thu, Sep 21, 2017

In pre-market opening, the 31-scrip index was trading lower at 32,406-level and that of 51-scrip index was below 10,140-mark.

Dr Reddy's Q4 net profit rises by 319%

Dr Reddy's Q4 net profit rises by 319%

Fri, May 12, 2017

GV Prasad, Co-Chairman and CEO of Dr Reddy's Laboratories said, “FY17 has been challenging year due to lack of new product approvals for the US market. However, our other geoghraphies delivered good performance with several new product launches.”

Dr Reddy's Laboratories Q4 review: Here's what to expect

Dr Reddy's Laboratories Q4 review: Here's what to expect

Fri, May 12, 2017

In Q3FY17, the company reported consolidated net profit of Rs 492.3 crore, down 15.94% year-on-year compared to Rs 585.7 crore in the corresponding period of the previous year.

Next set of Q4 corporate earnings, macro data, French elections result to drive equities this week

Next set of Q4 corporate earnings, macro data, French elections result to drive equities this week

Sun, May 07, 2017

According to experts, the stock markets this week will be guided by the fourth quarter (Q4) corporate earnings, macroeconomic data and French elections results.

Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore

Q3FY17: Dr Reddy's Laboratories' net profit down 19% at Rs 470 crore

Sat, Feb 04, 2017

GV Prasad, Co-chairman of Dr Reddy's Laboratories said, "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A cost across all our business."

USFDA to re-audit Dr Reddy's three plants in first quarter of 2017

USFDA to re-audit Dr Reddy's three plants in first quarter of 2017

Thu, Jan 12, 2017

US Food and Drug Administration (USFDA) will re-audit three manufacturing facilities of Dr Reddy's Laboratories in the current quarter.

What would a Hillary Clinton win mean for Indian Pharma?

What would a Hillary Clinton win mean for Indian Pharma?

Mon, Nov 07, 2016

The global generics sector saw a significant de-rating in YTD (year-to-date) in the CY2016 with 1-year forward P/E (price over equity) contracting by 34%, with the past one month itself witnessing an 11%.

Pharma stocks fall sharply as US drug pricing investigation nears completion

Pharma stocks fall sharply as US drug pricing investigation nears completion

Fri, Nov 04, 2016

Media reports suggest that the US Congress investigation into price hikes, that began in October 2014, may be nearing completion, culminating into charges of price collusion against companies / individuals by the year end.

FIPB to take up 19 investment proposals this week

FIPB to take up 19 investment proposals this week

Sun, Oct 23, 2016

Inter-ministerial body FIPB will this week take up 19 foreign investment proposals, including those of Dr Reddy's Laboratories and JC Decaux Advertising.

Dr Reddy's introduces Aripiprazole, USP tablets in US market; stock down 1.04%

Dr Reddy's introduces Aripiprazole, USP tablets in US market; stock down 1.04%

Thu, Oct 13, 2016

Dr Reddy's launched Aripiprazole and USP tablets in the United States (US) market on Thursday.

Dr Reddy gets listed on Dow Jones sustainability indices 2016

Dr Reddy gets listed on Dow Jones sustainability indices 2016

Tue, Sep 13, 2016

G V Prasad, Co-chairman and CEO of Dr Reddy's Laboratories said,” This listing has earned us the trust and respect of all stakeholders we serve. I see our inclusion in the Dow Jones indices as another validation of our commitment to sustainability in all aspects of our business.”

Sun, Dr Reddy's, Glenmark strengthen their US play

Sun, Dr Reddy's, Glenmark strengthen their US play

Mon, Jul 18, 2016

Domestic pharma players are in stiff competition in US market. Sun Pharma with its taking over of SPARC's ELEPSIA XR, while Dr. Reddy launching Omeprazole and Sodium bicarbonate capsules and that of Glenmark waiting for 62 ANDA's approval, plans to strenghthen their position in the US.

Brexit impact: Indian pharma seems immune, says Phillip Capital

Brexit impact: Indian pharma seems immune, says Phillip Capital

Mon, Jun 27, 2016

"Brexit has raised business concerns around the world about trade and currency fluctuations, but Indian pharma seems immune," Surya Patra and Mehul Sheth from Phillip Capital Research said in research note on June 24.

Dr Reddy's to buy eight ANDAs in US for Rs 2,300 crore

Dr Reddy's to buy eight ANDAs in US for Rs 2,300 crore

Sat, Jun 11, 2016

The company has a strong track record in the US market with over 79 filed ANDAs pending approval, of which we believe 18 have first-to-file status.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x